FDA proposes not to include semaglutide, tirzepatide, and liraglutide on the 503 Bulks List of drugs that can be legally compounded from bulk substances.
The U.S. House Appropriations Committee votes to approve a spending bill to fund FDA for fiscal year 2027.
FDA proposes not to include semaglutide, tirzepatide, and liraglutide on the 503 Bulks List of drugs that can be legally compounded from bulk substances.
The U.S. House Appropriations Committee votes to approve a spending bill to fund FDA for fiscal year 2027.
The CDER Office of Prescription Drug Promotion cautions Bayer that a video and TV ad for its Nubeqa omit important risk information and contain elements that make it difficult to comprehend the major statements.
An FDA advisory committee votes 6 to 3 against supporting AstraZeneca’s investigational breast cancer therapy camizestrant.
